Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Roger Kobayashi

Allergy & Immunology Omaha, NE Medical Doctor

NPI 1093707754 CMS profile 3523

2808 S 80 Ave, Ste 210, Omaha, NE 68124

Open in the dashboard

General payments

$45,421

167 records reported · program years 2019–2024

Research payments

$4,300

Paid to them · 3 records reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$232,913 paid to institutions, not to them · program years 2019–2024

Through program year 2024, Roger Kobayashi of Omaha, NE is reported in the CMS Open Payments database as having received $45,421 across 167 general payments and $4,300 in research payments paid to them. Separately, studies naming them as principal investigator received $232,913 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 89th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $1,004 3
2023 General $3,725 23
2023 Research $1,300 1
2022 General $20,594 16
2021 General $9,481 40
2020 General $1,667 27
2019 General $8,949 58
2019 Research $3,000 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Roger Kobayashi
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Roger Kobayashi were reported at $0. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Roger Kobayashi Allergy & Immunology median Middle half National median
2019 $8,949 $594 $163–$1,512 $163
2020 $1,667 $426 $106–$1,233 $114
2021 $9,481 $638 $157–$1,708 $132
2022 $20,594 $790 $205–$1,961 $149
2023 $3,725 $852 $220–$2,147 $160
2024 $1,004 $865 $203–$2,267 $164
2025 $0 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Octapharma USA, Inc. $39,965 76 payments
  2. Pfizer Inc. $2,653 12 payments
  3. CSL Behring $771 20 payments
  4. Horizon Therapeutics plc $326 11 payments
  5. Grifols Shared Services North America, Inc. $281 4 payments
  6. Grifols USA, LLC $257 4 payments
  7. Genentech, Inc. $212 2 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $149 7 payments
  9. VYNE Pharmaceuticals Inc. $125 1 payment
  10. Pharming Healthcare, Inc. $114 1 payment
  11. Other $568 29 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Honoraria $21,500 6 payments
  2. Travel and Lodging $14,879 23 payments
  3. Food and Beverage $4,578 124 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,665 1 payment
  5. Consulting Fee $1,563 3 payments
  6. Education $1,236 10 payments
Products named General payments · program years 2019–2024
  1. CUTAQUIG Immunology $24,342 47 payments
  2. OCTAGAM IMMUNE GLOBULIN (HUMAN) Immunology $14,928 32 payments
  3. OCTAGAM IMMUNE GLOBULIN (HUMAN) Immunology $1,723 2 payments
  4. PAXLOVID $740 1 payment
  5. Hizentra Immunology $470 14 payments
  6. Xembify $436 6 payments
  7. ACTIMMUNE $326 11 payments
  8. Xofluza $212 2 payments
  9. Hizentra Immunology $170 3 payments
  10. CUTAQUIG Immunology $125 5 payments
  11. Other $1,228 48 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2024
  1. Octapharma USA, Inc. $4,300 3 payments

Records

170 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Nebraska

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record